Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?

finance.yahoo.com · 2026-09-07

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.

TickrTrends take: Johnson & Johnson is a defensive healthcare stock that has been compared favorably to consumer staple peers in 2026. According to TickrTrends' current valuation analysis, JNJ is rated as overvalued, which suggests that investors considering this stock should monitor whether its defensive characteristics and performance relative to competitors like Coca-Cola and Procter & Gamble justify its current valuation multiples. A valuation-focused reader should watch for any divergence between JNJ's defensive appeal and whether it trades at a premium that adequately reflects its risk profile within the healthcare sector.

Read the full story at finance.yahoo.com →